$178.86
0.67% yesterday
NYSE, Nov 03, 10:00 pm CET

Charles River Laboratories International, Inc. Stock price

$178.86
+1.53 0.86% 1M
+59.42 49.75% 6M
-5.74 3.11% YTD
-3.62 1.98% 1Y
-38.30 17.64% 3Y
-58.59 24.67% 5Y
+110.34 161.03% 10Y
+135.59 313.36% 20Y
NYSE, Closing price Mon, Nov 03 2025
-1.21 0.67%

Key metrics

Basic
Market capitalization
$8.9b
Enterprise Value
$11.0b
Net debt
$2.2b
Cash
$182.9m
Shares outstanding
49.2m
Valuation (TTM | estimate)
P/E
negative | 17.5
P/S
2.2 | 2.2
EV/Sales
2.7 | 2.7
EV/FCF
19.0
P/B
2.6
Financial Health
Equity Ratio
46.0%
Return on Equity
0.3%
ROCE
7.2%
ROIC
24.8%
Debt/Equity
0.7
Financials (TTM | estimate)
Revenue
$4.0b | $4.0b
EBITDA
$673.4m | $1.0b
EBIT
$469.1m | $771.8m
Net Income
$-69.2m | $506.3m
Free Cash Flow
$578.5m
Growth (TTM | estimate)
Revenue
-1.2% | -0.6%
EBITDA
-11.8% | 49.0%
EBIT
-25.6% | 40.1%
Net Income
-116.0% | 4,815.4%
Free Cash Flow
18.8%
Margin (TTM | estimate)
Gross
35.0%
EBITDA
16.7% | 25.5%
EBIT
11.6%
Net
-1.7% | 12.6%
Free Cash Flow
14.4%
More
EPS
$-1.4
FCF per Share
$11.8
Short interest
4.9%
Employees
19k
Rev per Employee
$210.0k
Show more

Is Charles River Laboratories International, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

Charles River Laboratories International, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Charles River Laboratories International, Inc. forecast:

10x Buy
43%
13x Hold
57%

Analyst Opinions

23 Analysts have issued a Charles River Laboratories International, Inc. forecast:

Buy
43%
Hold
57%

Financial data from Charles River Laboratories International, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4,029 4,029
1% 1%
100%
- Direct Costs 2,618 2,618
0% 0%
65%
1,411 1,411
4% 4%
35%
- Selling and Administrative Expenses 738 738
5% 5%
18%
- Research and Development Expense - -
-
-
673 673
12% 12%
17%
- Depreciation and Amortization 204 204
53% 53%
5%
EBIT (Operating Income) EBIT 469 469
26% 26%
12%
Net Profit -69 -69
116% 116%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Charles River Laboratories International, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Charles River Laboratories International, Inc. Stock News

Neutral
PRNewsWire
7 days ago
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Oct. 27, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to shareholders.
Neutral
Business Wire
11 days ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to shareholders. If you currently own Charles River stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to ...
Neutral
Business Wire
13 days ago
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and The Francis Crick Institute (Crick) today announced a new collaboration around Antibody-Drug Conjugate (ADC) drug discovery and development, leveraging combined strengths to accelerate the development and delivery of next-generation targeted therapies. This agreement leverages an in...
More Charles River Laboratories International, Inc. News

Company Profile

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client's use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Head office United States
CEO James Foster
Employees 19,400
Founded 1947
Website www.criver.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today